Autonomic Determinants of POTS - Pilot 2

Autonomic Determinants of Postural Tachycardia Syndrome (Chronic Pilot Study 2)

Sponsors

Lead Sponsor: Vanderbilt University Medical Center

Collaborator: National Heart, Lung, and Blood Institute (NHLBI)

Source Vanderbilt University Medical Center
Brief Summary

Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. These patients have high heart rate and disabling symptoms during standing. Quality of life may be poor. The sympathetic nerves in the autonomic nervous system help to maintain normal blood pressures and heart rates during activities of daily life. The purpose of this study is to determine the importance of sympathetic activation as a cause of orthostatic symptoms. The investigators will assess the effects of a blood pressure medication (Moxonidine) on the symptoms during standing. Moxonidine lowers sympathetic activity. The investigators believe patients with high resting sympathetic activity might benefit from Moxonidine. It might reduce high heart rate and improve symptoms during standing. This study should help clinicians and the growing population of patients with POTS gain a better understanding of this disorder and find more personalized treatment.

Detailed Description

Patients with POTS experience symptoms and an increase in heart rate≥30 beats/min with standing in the absence of orthostatic hypotension. As a result of considerable functional impairment, individuals with POTS are often unable to attend school or work. There is agreement that POTS is a heterogeneous disorder with multiple overlapping pathophysiologies proposed to underlie the clinical phenotype of patients. It would be important to define the underlying pathophysiological mechanisms in an individual patient to design optimal therapy. Our overarching hypothesis is that there is a subset of POTS patients (psPOTS) with a central sympathetic activation as the primary pathophysiology. We have characterized these patients by an increase in muscle sympathetic nerve activity (MSNA, a reflection of central sympathetic outflow) even at rest. In this project, we will focus on the role of primary sympathetic activation in the pathogenesis of POTS. Direct neural recordings of sympathetic activity, central sympathetic inhibition and extensive autonomic phenotyping will enable us to identify and correct the primary pathophysiology to optimally benefit psPOTS patients. This is a mechanistic study, designed to assess the effects of 4 weeks of central sympatholysis with moxonidine on orthostatic tachycardia and symptoms (Specific Aim 1), hypovolemia (Specific Aim 2) and central and peripheral baroreflex properties (Specific Aim 3) in a randomized, crossover design with POTS patients having elevated resting sympathetic nerve activity.

Overall Status Not yet recruiting
Start Date 2021-06-01
Completion Date 2025-12-31
Primary Completion Date 2025-01-01
Phase Early Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
Change in Orthostatic Symptom Burden [delta (delta VOSS)] after 30 min supine to after 15 min of 60 degrees upright tilt (delta VOSS), 2-3 hours after a dose of the treatment assigned for the previous 4 weeks.
Secondary Outcome
Measure Time Frame
Change in Orthostatic Change in Heart Rate [delta (delta HR)] after 30 min supine to after 15 min of 60 degrees upright tilt (delta HR), 2-3 hours after a dose of the treatment assigned for the previous 4 weeks.
Enrollment 48
Condition
Intervention

Intervention Type: Drug

Intervention Name: Placebo oral tablet

Description: Placebo pill identical to moxonidine administered for 4 weeks

Other Name: inactive pill

Intervention Type: Drug

Intervention Name: Moxonidine Pill

Description: Moxonidine pill administered for 4 weeks

Other Name: Physiotens

Eligibility

Criteria:

Inclusion Criteria: - meets criteria for postural tachycardia syndrome (POTS) 1. a heart rate increase of ≥30 beats/min within 10 minutes of upright posture; 2. lack of orthostatic hypotension (blood pressure fall ≥ 20/10 mmHg within 3 minutes of standing); and 3. chronic symptoms during upright posture over at least 6 months, in the absence of any other acute cause. - in the follicular phase of the menstrual cycle (days 5-13 of a 28-day cycle) - POTS with primary central sympathetic activation (psPOTS) as defined as having resting MSNA ≥ 25 bursts/min - able and willing to provide informed consent. Exclusion Criteria: - pregnancy, - smoker, - BMI>30 kg/m2, - deconditioned status (if available VO2max<80% of predicted) - unable to withdraw from medications known to affect autonomic function, blood pressure or blood volume - systemic illnesses known to produce autonomic neuropathy, including but not limited to diabetes mellitus, amyloidosis, monoclonal gammopathies, and autoimmune neuropathies. - arteriosclerotic disease of carotid artery. History of neck surgery. - conditions associated with inflammatory processes, such as coronary artery disease, hypertension, smoking, hypercholesterolemia (or on statin therapy), rheumatoid arthritis, diabetes, - treatment with oral corticosteroids, current infections (e.g., urinary tract infection), or use of non-steroidal anti-inflammatory drugs. - other factors which in the investigator's opinion would prevent the subject from completing the protocol including clinically significant abnormalities in clinical, mental or laboratory testing.

Gender:

Female

Minimum Age:

18 Years

Maximum Age:

55 Years

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
André Diedrich, MD Principal Investigator Vanderbilt University Medical Center
Overall Contact

Last Name: Emily C Smith, RN

Phone: 615 875-1516

Phone Ext.: 6153436833

Email: [email protected]

Verification Date

2020-12-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Vanderbilt University Medical Center

Investigator Full Name: Andre' Diedrich

Investigator Title: Research Professor of Medicine

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Moxonidine then Placebo

Type: Experimental

Description: After 5 days of screening/baseline evaluations, patients will be discharged home on moxonidine 0.2-0.4 mg/day PO. On days 29, 30 and 31, the patients will be re-admitted for study testing while on moxonidine. At completion of this testing, patients will start taking matching placebo once daily PO to be continued at home. On days 58, 59 and 60, the patients will be re-admitted for study testing while on placebo.

Label: Placebo then Moxonidine

Type: Experimental

Description: After 5 days of screening/baseline evaluations, patients will be discharged home on placebo identical to moxonidine once daily PO. On days 29, 30 and 31, the patients will be re-admitted for study testing while on placebo. At completion of this testing, patients will start taking moxonidine 0.2-0.4 mg/day PO to be continued at home. On days 58, 59 and 60, the patients will be re-admitted for study testing while on moxonidine.

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Crossover Assignment

Intervention Model Description: randomized, double blind, crossover design

Primary Purpose: Other

Masking: Double (Participant, Investigator)

Masking Description: Vanderbilt's Investigational Pharmacy will randomly assign participants to the moxonidine/placebo or placebo/moxonidine arm of the study. They will also provide the active drug and matching placebo. The medication distribution list will be kept by a dedicated person not involved in the study.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News